These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 33534004)

  • 1. Chromosome X aneusomy and androgen receptor gene copy number aberrations in apocrine carcinoma of the breast.
    Cremonini A; Saragoni L; Morandi L; Corradini AG; Ravaioli C; Di Oto E; Limarzi F; Sanchez AM; Cucchi MC; Masetti R; Quinn C; Foschini MP
    Virchows Arch; 2021 Aug; 479(2):345-354. PubMed ID: 33534004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. X chromosome gain is related to increased androgen receptor expression in male breast cancer.
    Di Oto E; Biserni GB; Varga Z; Morandi L; Cucchi MC; Masetti R; Foschini MP
    Virchows Arch; 2018 Aug; 473(2):155-163. PubMed ID: 29802469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen Receptor Gene Copy Number and Protein Expression in Treatment-Naïve Prostate Cancer.
    Poelaert F; Kumps C; Lumen N; Verschuere S; Libbrecht L; Praet M; Rottey S; Claeys T; Ost P; Decaestecker K; De Meerleer G; Van Praet C
    Urol Int; 2017; 99(2):222-228. PubMed ID: 28052297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromosome 7 aneusomy in metaplastic breast carcinomas with chondroid, squamous, and spindle-cell differentiation.
    Gwin K; Lezon-Geyda K; Harris L; Tavassoli FA
    Int J Surg Pathol; 2011 Feb; 19(1):20-5. PubMed ID: 19411277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Update on the Molecular and Clinical Characteristics of Apocrine Carcinoma of the Breast.
    Vranic S; Gatalica Z
    Clin Breast Cancer; 2022 Jun; 22(4):e576-e585. PubMed ID: 35027319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic value of androgen receptors in breast cancer subtypes.
    Kraby MR; Valla M; Opdahl S; Haugen OA; Sawicka JE; Engstrøm MJ; Bofin AM
    Breast Cancer Res Treat; 2018 Nov; 172(2):283-296. PubMed ID: 30109519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast.
    Vranic S; Marchiò C; Castellano I; Botta C; Scalzo MS; Bender RP; Payan-Gomez C; di Cantogno LV; Gugliotta P; Tondat F; di Celle PF; Mariani S; Gatalica Z; Sapino A
    Hum Pathol; 2015 Sep; 46(9):1350-9. PubMed ID: 26208846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer.
    Gupta S; Vanderbilt C; Abida W; Fine SW; Tickoo SK; Al-Ahmadie HA; Chen YB; Sirintrapun SJ; Chadalavada K; Nanjangud GJ; Bialik A; Morris MJ; Scher HI; Ladanyi M; Reuter VE; Gopalan A
    Prostate Cancer Prostatic Dis; 2020 Sep; 23(3):507-516. PubMed ID: 32094488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amplification of the androgen receptor may not explain the development of androgen-independent prostate cancer.
    Edwards J; Krishna NS; Mukherjee R; Watters AD; Underwood MA; Bartlett JM
    BJU Int; 2001 Oct; 88(6):633-7. PubMed ID: 11678763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bilateral apocrine carcinoma of the breast. Molecular and immunocytochemical evidence for two independent primary tumours.
    Schmitt FC; Soares R; Seruca R
    Virchows Arch; 1998 Dec; 433(6):505-9. PubMed ID: 9870682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity.
    Lin Fde M; Pincerato KM; Bacchi CE; Baracat EC; Carvalho FM
    J Clin Pathol; 2012 Jan; 65(1):64-8. PubMed ID: 22039288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apocrine lesions of the breast: part 2 of a two-part review. Invasive apocrine carcinoma, the molecular apocrine signature and utility of immunohistochemistry in the diagnosis of apocrine lesions of the breast.
    D'Arcy C; Quinn CM
    J Clin Pathol; 2019 Jan; 72(1):7-11. PubMed ID: 30425121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity.
    Moore NL; Buchanan G; Harris JM; Selth LA; Bianco-Miotto T; Hanson AR; Birrell SN; Butler LM; Hickey TE; Tilley WD
    Endocr Relat Cancer; 2012 Aug; 19(4):599-613. PubMed ID: 22719059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptor expression predicts breast cancer survival: the role of genetic and epigenetic events.
    Peters KM; Edwards SL; Nair SS; French JD; Bailey PJ; Salkield K; Stein S; Wagner S; Francis GD; Clark SJ; Brown MA
    BMC Cancer; 2012 Apr; 12():132. PubMed ID: 22471922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ.
    Gatalica Z
    Pathol Res Pract; 1997; 193(11-12):753-8. PubMed ID: 9521507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast.
    Honma N; Takubo K; Akiyama F; Sawabe M; Arai T; Younes M; Kasumi F; Sakamoto G
    Histopathology; 2005 Aug; 47(2):195-201. PubMed ID: 16045781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pure Apocrine Carcinomas Represent a Clinicopathologically Distinct Androgen Receptor-Positive Subset of Triple-Negative Breast Cancers.
    Mills AM; E Gottlieb C; M Wendroth S; M Brenin C; Atkins KA
    Am J Surg Pathol; 2016 Aug; 40(8):1109-16. PubMed ID: 27259012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen deprivation by adrenal suppression using low-dose hydrocortisone for the treatment of breast carcinoma with apocrine features: a case report illustrating this new paradigm.
    Jongen L; Paridaens R; Floris G; Wildiers H; Neven P
    Breast Cancer Res Treat; 2016 Feb; 155(3):603-7. PubMed ID: 26868122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
    Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
    BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.